# ACXP (Acurx Pharmaceuticals, Inc.) - SEC EDGAR Financial Statements

> Acurx Pharmaceuticals, Inc. reported $10.34M in total assets and a net loss of $8.10M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/ACXP
- Markdown: https://convexityos.com/fundamentals/ACXP.md
- SEC CIK: 0001736243
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:08 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001736243&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$8.27M | Operating profit |
| Net Income | FY 2025 | -$8.10M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$1.52 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $9.65M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $1.83M | $5.40M | $6.04M | $4.75M | $2.03M | $2.20M |
| Selling, General & Admin | -- | -- | -- | -- | $208K | -- |
| Total Operating Expenses | $8.09M | $14.12M | $14.58M | $12.09M | $12.81M | $4.60M |
| **Operating Income** | -$8.09M | -$14.12M | -- | -- | -- | -- |
| Interest Income | $125K | $20K | -- | -- | -- | -- |
| Income Tax Expense | -- | -- | -- | $0 | -- | $0 |
| **Net Income** | -$7.97M | -$14.10M | -$14.58M | -$12.09M | -$12.75M | -$4.60M |
| Basic EPS | -$5.32 | -$17.45 | -$23.00 | -$22.40 | -$29.80 | -$14.80 |
| **Diluted EPS** | -$5.32 | -$17.45 | -$23.00 | -$22.40 | -$29.80 | -$14.80 |
| Basic Shares Outstanding | 1.5M | 808.2K | 633.6K | 540.8K | 426.8K | 309.5K |
| Diluted Shares Outstanding | 1.5M | 808.2K | 633.6K | 540.8K | 426.8K | 309.5K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $1.12M | $1.07M | $341K | $282K | $430K | $524K | $599K | $825K |
| Total Operating Expenses | $2.63M | $2.31M | $1.72M | $1.62M | $2.03M | $2.27M | $2.18M | $2.79M |
| **Operating Income** | -$2.63M | -$2.31M | -$1.72M | -$1.62M | -$2.03M | -$2.27M | -$2.18M | -- |
| Interest Income | $48K | $53K | $35K | $39K | $36K | $23K | $27K | -- |
| **Net Income** | -$2.58M | -$2.25M | -$1.68M | -$1.58M | -$1.99M | -$2.25M | -$2.15M | -$2.78M |
| Basic EPS | -$0.49 | -$0.53 | -$0.62 | -- | -$1.23 | -$1.89 | -$2.15 | -- |
| **Diluted EPS** | -$0.49 | -$0.53 | -$0.62 | -- | -$1.23 | -$1.89 | -$2.15 | -- |
| Basic Shares Outstanding | 5.3M | 4.3M | 2.7M | -- | 1.6M | 1.2M | 1.0M | -- |
| Diluted Shares Outstanding | 5.3M | 4.3M | 2.7M | -- | 1.6M | 1.2M | 1.0M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $7.56M | $3.71M | $7.47M | $9.11M | $12.96M | $3.18M |
| **Cash & Short-Term Investments** | $7.56M | $3.71M | $7.47M | $9.11M | $12.96M | $3.18M |
| **Total Current Assets** | -- | $3.86M | $7.71M | $9.38M | $13.25M | -- |
| **Total Non-Current Assets** | -- | $0 | $0 | $0 | $0 | -- |
| **Total Assets** | $7.69M | $3.86M | $7.71M | $9.38M | $13.25M | $3.22M |
| **Total Current Liabilities** | $2.42M | $3.24M | $3.04M | $2.06M | $844K | $473K |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $50K |
| **Total Liabilities** | $2.42M | $3.24M | $3.04M | $2.06M | $844K | $522K |
| Common Stock | $2.3K | $852 | $14K | $12K | $10K | -- |
| Retained Earnings | -$75.29M | -$67.32M | -$53.22M | -$38.64M | -$26.55M | -$13.80M |
| **Total Stockholders' Equity** | $5.27M | $615K | $4.67M | $7.32M | $12.41M | $2.70M |
| Total Equity | $5.27M | $615K | $4.67M | $7.32M | $12.41M | $2.70M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Dec 2024 | Jun 2024 | Mar 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $9.65M | $10.66M | $9.25M | $7.56M | $5.91M | $3.71M | $6.36M | $8.92M |
| **Cash & Short-Term Investments** | $9.65M | $10.66M | $9.25M | $7.56M | $5.91M | $3.71M | $6.36M | $8.92M |
| **Total Current Assets** | -- | -- | -- | -- | -- | $3.86M | -- | -- |
| **Total Non-Current Assets** | -- | -- | -- | -- | -- | $0 | -- | -- |
| **Total Assets** | $10.34M | $10.98M | $9.54M | $7.69M | $6.11M | $3.86M | $6.58M | $9.11M |
| **Total Current Liabilities** | $2.99M | $2.83M | $2.53M | $2.42M | $2.47M | $3.24M | $3.15M | $3.11M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $2.99M | $2.83M | $2.53M | $2.42M | $2.47M | $3.24M | $3.15M | $3.11M |
| Common Stock | $5.9K | $4.7K | $3.4K | $2.3K | $1.8K | $852 | $16K | $16K |
| Retained Earnings | -$81.81M | -$79.22M | -$76.97M | -$75.29M | -$73.71M | -$67.32M | -$61.72M | -$57.60M |
| **Total Stockholders' Equity** | $7.34M | $8.15M | $7.01M | $5.27M | $3.64M | $615K | $3.43M | $6.00M |
| Total Equity | $7.34M | $8.15M | $7.01M | $5.27M | $3.64M | $615K | $3.43M | $6.00M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$7.97M | -$14.10M | -$14.58M | -$12.09M | -$12.75M | -$4.60M |
| Stock-Based Compensation | $1.25M | $2.60M | $3.21M | $2.87M | $5.15M | $696K |
| **Operating Cash Flow** | -$6.79M | -$10.38M | -$9.80M | -$7.54M | -$5.01M | -$3.35M |
| Common Stock Issued | -- | -- | -- | $3.70M | -- | -- |
| **Financing Cash Flow** | $10.64M | $6.62M | $8.16M | $3.70M | $14.80M | $4.04M |
| **Net Change in Cash** | $3.85M | -$3.77M | -$1.64M | -$3.85M | $9.78M | $692K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$2.58M | -$2.25M | -$1.68M | -$1.58M | -$1.99M | -$2.25M | -$2.15M | -$2.78M |
| Stock-Based Compensation | $208K | $201K | $258K | $295K | $295K | $324K | $334K | $345K |
| **Operating Cash Flow** | -$2.49M | -$1.71M | -$1.41M | -$1.18M | -$1.88M | -$1.67M | -$2.05M | -$2.25M |
| **Financing Cash Flow** | $1.49M | $3.11M | $3.11M | $2.83M | $1.72M | $3.09M | $2.99M | $195K |
| **Net Change in Cash** | -$1.00M | $1.40M | $1.70M | $1.65M | -$157K | $1.42M | $937K | -$2.06M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -151.2% | -2292.7% | -312.4% | -165.3% | -102.7% | -170.3% |
| Return on Assets (ROA) | -103.6% | -365.6% | -189.1% | -129.0% | -96.2% | -142.7% |
| Current Ratio | -- | 1.19x | 2.53x | 4.55x | 15.71x | -- |
| Quick Ratio | 3.12x | 1.14x | 2.46x | 4.42x | 15.36x | 6.72x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -110.3% | -92.1% | -106.9% | -151.2% | -252.1% | -- | -- | -2292.7% |
| Return on Assets (ROA) | -78.3% | -68.3% | -78.6% | -103.6% | -150.2% | -- | -- | -365.6% |
| Current Ratio | -- | -- | -- | -- | -- | -- | -- | 1.19x |
| Quick Ratio | 3.23x | 3.76x | 3.66x | 3.12x | 2.39x | -- | -- | 1.14x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
